SAMANSIC COALITION – SCIENTIFIC REPORT

A Precision Nutritional Framework for Neuroprotection and Stress-Related Disorders: Integrating Peptide-Based Supplementation, SUMOylation Pathway Modulation, and the KAN V1.0 AI Architecture

​

I. Executive Summary

This scientific report presents the foundational framework, mechanistic rationale, taxonomic classification, therapeutic landscape, and strategic market positioning of the SAMANSIC Coalition's dual-use neuroprotective and stress-related disorder intervention platform. The core innovations center on three interdependent technologies. First, DK-NEURO R150 is a peptide-based nutritional supplement designed to mitigate neurodegenerative processes and nervous system dysfunction, particularly in the context of post-traumatic stress disorder (PTSD) and related stress-induced pathologies. Second, the SUMOylation modulation protocol, known as the "Four Pillars" and comprising magnesium, N-acetylcysteine, alpha-ketoglutarate, and B-complex vitamins, targets small ubiquitin-like modifier conjugation to enhance mitochondrial homeostasis, reduce neuroinflammation, and protect against stress-induced neuronal damage. Third, the KAN V1.0 artificial intelligence engine serves as a multi-omic integration platform that synthesizes genomic, microbiomic, and clinical data to generate phenotype-specific formulations for precision neuro-nutrition.

​

The report synthesizes peer-reviewed mechanistic data from 2023 to 2025, clinical treatment standards from authoritative bodies including the Mayo Clinic, the American Psychological Association, and the United Kingdom's National Health Service, and market projections extending through 2033 to 2036. This synthesis positions SAMANSIC's intervention within a PTSD treatment market valued at approximately $16.8 billion in 2023 and projected to reach $27.37 billion by 2033, as well as within the broader longevity economy anticipated to approach $1.7 trillion by 2036. Critically, while the mechanistic rationale is grounded in legitimate preclinical literature, the transition to human clinical validation remains the essential path forward, and the report does not claim established efficacy but rather proposes a testable scientific hypothesis.

​

II. Introduction and Scope

​

Background and Rationale

Neurodegenerative and stress-related disorders, including PTSD, Parkinson's disease, and age-related cognitive decline, share common pathophysiological drivers that transcend their distinct diagnostic categories. These shared mechanisms include chronic oxidative stress resulting from an imbalance between reactive oxygen species production and antioxidant defense capacity, mitochondrial dysfunction characterized by impaired energy production and increased apoptotic signaling, neuroinflammation driven by persistent glial activation and pro-inflammatory cytokine release, and dysregulated protein aggregation involving abnormal accumulation of misfolded proteins that disrupt neuronal signaling and ultimately lead to cell death.

Current pharmacotherapies for PTSD and related conditions, primarily consisting of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors such as paroxetine, sertraline, fluoxetine, and venlafaxine, address symptomatic manifestations but do not modify underlying disease mechanisms. Furthermore, a substantial proportion of patients demonstrate inadequate response to these agents, and none of the currently approved medications target the fundamental molecular pathways that drive stress-induced neurodegeneration or the persistent fear conditioning that characterizes PTSD.

​

SAMANSIC's Scientific Thesis

The SAMANSIC Coalition advances the scientific thesis that targeting post-translational modifications, specifically SUMOylation, offers a novel mechanism to restore neuronal resilience and modify disease progression rather than merely managing symptoms. According to this framework, the DK-NEURO R150 peptide complex and the SUMO-supportive Four Pillars protocol act synergistically through three primary mechanisms. First, they reduce stress hormone-induced excitotoxicity by mitigating the damaging effects of excessive or chronic adrenaline secretion on neural networks. Second, they enhance mitochondrial quality control via the mitochondrial unfolded protein response and mitophagy, the process of clearing damaged mitochondria. Third, they modulate glucocorticoid receptor and FKBP51 complexes that have been shown to be elevated in PTSD patients compared with trauma-exposed individuals without PTSD and patients with major depressive disorder.

​

Scope of This Report

This report encompasses four major domains of inquiry. The first domain is the taxonomic classification of PTSD subtypes, providing a clinical framework for understanding the heterogeneity of stress responses and the implications for targeted intervention. The second domain is the mechanistic rationale for peptide-based and SUMO-targeted nutritional strategies, drawing on peer-reviewed literature from 2023 to 2025. The third domain is a comparative analysis of SAMANSIC's proposed approach against existing treatment standards from the Mayo Clinic, the American Psychological Association, and the National Health Service. The fourth domain is market analysis and strategic positioning for the 2023 to 2036 period, including regulatory and clinical validation roadmaps.

​

III. Taxonomic Framework for Post-Traumatic Stress Disorder

​

Definition and Epidemiology

Post-traumatic stress disorder is a mental health condition that occurs after a person experiences or witnesses a life-threatening event, including but not limited to violence, accidents, natural disasters, combat, sexual assault, or serious medical procedures. The disorder is characterized by four clusters of persistent and intrusive symptoms, specifically re-experiencing the traumatic event through flashbacks or nightmares, avoidance of reminders associated with the trauma, negative alterations in cognition and mood, and hyperarousal manifesting as exaggerated startle response or hypervigilance.

​

The prevalence of PTSD in the general population is estimated at approximately eight percent, with substantially higher rates observed among military personnel, veterans, first responders, and individuals who have experienced repeated or prolonged trauma. PTSD is associated with significant impairment in social, occupational, and physical functioning, as well as increased risk of comorbid mental disorders including major depression, anxiety disorders, and substance use disorders, and physical disorders including cardiovascular disease and chronic pain syndromes.

​

Proposed Subtypes of PTSD

Although PTSD is often conceptualized as a unitary diagnosis, recent research has demonstrated that there are distinct subtypes that may have different etiologies, clinical features, and treatment responses. Based on the nature and number of traumatic events, the onset and duration of symptoms, and the presence of other mental health problems, five subtypes have been identified and are described below.

​

The first subtype is normal stress response, which is a transient and adaptive reaction to a single, mild to moderate traumatic event such as a car accident, injury, or surgery. This subtype involves emotional distress, physiological arousal, and cognitive disruption but does not interfere with daily functioning. Normal stress response usually resolves within a few weeks with the help of social support and coping strategies. It does not require formal treatment but may benefit from psychoeducation and counseling.

​

The second subtype is acute stress disorder, which is a severe and impairing response to a single, intense traumatic event such as a natural disaster, violent assault, or loss of a loved one. This subtype involves similar symptoms to PTSD, but they occur within one month of the trauma and last for at least three days. Acute stress disorder may indicate a high risk of developing full PTSD if left untreated, and it can be effectively treated with trauma-focused psychotherapy, pharmacotherapy, or a combination of both approaches.

​

The third subtype is uncomplicated PTSD, which is a chronic and disabling response to a single, major traumatic event such as combat exposure, rape, or terrorist attack. This subtype involves persistent and intrusive symptoms of PTSD that last for more than one month and cause significant distress and impairment. Uncomplicated PTSD can be effectively treated with evidence-based interventions including cognitive-behavioral therapy, eye movement desensitization and reprocessing, or selective serotonin reuptake inhibitors.

The fourth subtype is complex PTSD, which is a multifaceted and pervasive response to multiple, prolonged, or repeated traumatic events such as childhood abuse, domestic violence, or captivity. This subtype involves not only the core symptoms of PTSD but also additional features including affective dysregulation, dissociation, identity disturbances, interpersonal problems, and somatic complaints. Complex PTSD may be associated with other mental disorders such as borderline personality disorder, dissociative disorders, or substance use disorders, and it requires a comprehensive and long-term treatment approach that addresses both the trauma-related and the personality-related aspects of the condition.

​

The fifth subtype is comorbid PTSD, which is a complicated and heterogeneous response to one or more traumatic events that co-occurs with other mental or physical disorders including depression, anxiety, bipolar disorder, schizophrenia, or chronic pain. Comorbid PTSD may exacerbate the symptoms and impair the outcomes of both the PTSD and the comorbid condition. This subtype requires a coordinated and integrated treatment plan that targets both the PTSD and the comorbid condition simultaneously or sequentially, depending on the severity and priority of each disorder.

​

Molecular Correlates: The Glucocorticoid Receptor and FKBP51 Complex

A significant molecular finding in PTSD research concerns the glucocorticoid receptor and FK506 binding protein 51 complex. Studies have demonstrated that this protein complex is elevated in PTSD patients compared with unaffected control subjects, subjects exposed to trauma without PTSD, and patients with major depressive disorder. This complex may contribute to fear conditioning and the persistence of PTSD symptoms, and it represents a potential therapeutic target for preventing or treating PTSD. The SAMANSIC nutritional intervention is hypothesized to modulate this complex, though this remains a hypothesis requiring direct experimental validation.

​

IV. Mechanistic Rationale for DK-NEURO R150 and the SUMO Pathway

​

Peptide Therapeutics in Neuroprotection

The advancement of science in the fields of biology and biomedicine has led to the discovery and isolation of numerous peptides with biological activity from natural animal and plant sources. Bioactive peptides derived from sources such as milk, fermented dairy products, cold-water fish, whole grains, fruits, and vegetables have demonstrated a range of neuroprotective properties. These properties include neurotrophic effects that support neuronal survival and differentiation, anti-inflammatory actions that reduce glial activation and cytokine release, and modulation of protein aggregation pathways that may interfere with the pathological accumulation of misfolded proteins in or on neurons, which disrupts signaling and eventually kills neurons.

​

Scientific studies have demonstrated a correlation between the consumption of these bioactive components and the prevention of chronic diseases. Additional bioactive components such as carotenoids, antioxidants, and essential oils are also present in foods and enhance their nutritional value or sensory characteristics. The global peptide therapeutics market reflects growing acceptance of these interventions, having grown from $37.26 billion in 2022 to $40.7 billion in 2023 at a compound annual growth rate of 9.2 percent.

​

Stress Hormone Excitotoxicity

Adrenaline is a hormone that the body secretes in situations of danger, excitement, or stress, and it stimulates the fight-or-flight response. This response leads to increased heart rate, dilated airways, and increased blood pressure and blood sugar, which increases brain alertness and muscle movement. However, excessive or frequent secretion of adrenaline can damage neural networks and nerve cells in the body through several mechanisms.

​

First, adrenaline causes the release of chemicals such as glutamate and calcium in nerve cells, and these substances lead to excessive activation of nerve cells, which can cause damage or death to nerve cells through excitotoxicity. Second, adrenaline causes blood vessels in some parts of the brain to constrict, reducing blood flow and oxygen delivery to those regions, and this can cause nerve cell damage or death through ischemic mechanisms. Third, adrenaline causes changes in the chemical and hormonal balance in the body, which can affect the functions of the brain and nervous system and cause psychological disorders such as anxiety, depression, and post-traumatic stress disorder.

​

Therefore, it is important to learn how to get rid of excess adrenaline in the body, and methods that help in this regard include modifying a healthy and balanced lifestyle, eating a nutritious diet, compensating for nutritional deficiencies with nutrients, ensuring adequate sleep, and utilizing herbal or aromatherapy approaches. The DK-NEURO R150 supplement is positioned as a vital nutritional intervention that uses peptides to help counteract these stress-induced damage pathways.

​

DK-NEURO R150 Composition and Proposed Mechanism

DK-NEURO R150 is formulated as a vital nutritional supplement that uses bioactive peptides to help combat various nervous system diseases. Neurodegenerative diseases are typically caused by abnormal aggregations of proteins or peptides, and the deposition of these aggregates in or on neurons disrupts signaling and eventually kills neurons. The proposed mechanism of DK-NEURO R150 involves the peptides interfering with these pathological aggregation processes, reducing oxidative stress through antioxidant activity, and supporting neuronal signaling integrity through neurotrophic effects. It is important to note that while these mechanisms are plausible based on the general properties of bioactive peptides, specific published clinical data on DK-NEURO R150 itself has not been provided in this report.

​

SUMOylation as a Core Protective Mechanism

SUMOylation refers to the covalent attachment of small ubiquitin-like modifier proteins to target proteins, a post-translational modification that regulates protein function, stability, and subcellular localization. Preclinical studies have demonstrated that SUMOylation plays a critical role in cellular stress responses, including the response to oxidative stress, heat shock, and ischemic injury. Specifically in the nervous system, SUMOylation has been shown to protect neurons from various insults by stabilizing mitochondrial membranes, reducing excitotoxicity, and modulating inflammatory signaling.

​

Studies in Caenorhabditis elegans have shown that knocking down the SUMO gene shortens lifespan, while overexpression of SUMO extends it, with the mechanism involving mitochondrial homeostasis and mitophagy. The Four Pillars protocol of magnesium, N-acetylcysteine, alpha-ketoglutarate, and B-complex vitamins is hypothesized to enhance SUMOylation activity, though direct evidence in humans is currently lacking and represents a critical validation imperative.

​

V. Comparative Analysis of Current PTSD Treatment Standards

​

Authoritative Guidelines from the Mayo Clinic

According to the Mayo Clinic, the primary treatment for PTSD is psychotherapy, which can help patients regain a sense of control over their lives and cope with their symptoms. Several types of psychotherapy are effective for PTSD, including cognitive behavioral therapy, cognitive processing therapy, cognitive therapy, and prolonged exposure therapy. These therapies help patients modify and challenge negative beliefs and emotions related to the trauma and gradually face situations and memories that they find frightening.

​

In some cases, medication may also be used to treat PTSD, especially if patients have other mental health problems such as depression or anxiety. The Mayo Clinic notes that treatment may vary depending on individual needs, preferences, and circumstances, and it emphasizes the importance of consulting with a qualified mental health professional who can assess the condition and recommend the best course of action.

​

Guidelines from the American Psychological Association

The American Psychological Association recommends four medications for PTSD: paroxetine, sertraline, fluoxetine, and venlafaxine. These are all antidepressants that belong to the class of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. They work by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters that regulate mood and stress response. The APA also strongly recommends trauma-focused psychotherapies as first-line treatment.

​

Guidelines from the National Health Service of the United Kingdom

The National Health Service of the United Kingdom recommends paroxetine and sertraline as the first-line medications for PTSD in adults. However, these medicines are only used if the patient chooses not to have trauma-focused psychological treatment, or if they have tried it and it has not helped, or if they have severe symptoms that interfere with daily functioning. The NHS emphasizes that psychological therapies are preferred over medication whenever feasible.

​

Gaps in Current Treatment and Positioning of SAMANSIC's Approach

Despite the availability of these evidence-based treatments, significant gaps remain in the management of PTSD. There are currently no disease-modifying therapies that target the underlying pathophysiology of PTSD, as opposed to symptom management. A substantial proportion of patients, estimated at thirty to fifty percent depending on the study, do not achieve adequate response to first-line SSRIs or SNRIs. Furthermore, there is a lack of interventions specifically targeting the molecular drivers of PTSD, including the glucocorticoid receptor-FKBP51 complex, mitochondrial dysfunction, and SUMOylation dysregulation.

​

The SAMANSIC approach is positioned to address these gaps as an adjunctive nutritional intervention designed to enhance biological resilience and reduce excitotoxicity. It is proposed as a potential preventive strategy for at-risk populations including military personnel, first responders, and trauma-exposed individuals. Finally, it offers a bridge toward precision neuro-nutrition through the KAN V1.0 personalization engine, which tailors interventions to individual molecular profiles rather than applying a one-size-fits-all approach.

​

VI. Market Analysis for PTSD Treatment and Related Indications

​

Global PTSD Treatment Market

The global post-traumatic stress disorder treatment market was valued at approximately $16.8 billion in 2023 and is projected to accumulate a market value of $27.37 billion by 2033, registering a compound annual growth rate of five percent over the forecast period. For comparison, the market registered a compound annual growth rate of 3.3 percent in the historical period from 2018 to 2022, indicating accelerating growth.

​

Key Growth Drivers

Several factors are driving the expansion of the PTSD treatment market.

 

• First, increasing awareness about mental health and the need for seeking treatment for mental health issues has reduced stigma and encouraged more individuals to seek help. People are more willing to seek support for their mental health problems, and they have more options for PTSD treatment than in previous decades, including innovative approaches such as virtual reality therapy.

• Second, there is rising demand for personalized medicine and targeted therapies that can cater to the specific needs of each patient, moving beyond the traditional one-size-fits-all approach that has characterized much of psychiatric pharmacotherapy.

• Third, governments around the world are supporting mental health programs and initiatives, funding mental health research and treatment programs to enhance the quality of life for people with PTSD.

• Fourth, innovation in therapy modalities continues to expand the available options, including new psychotherapeutic techniques, novel pharmacologic agents, and digital therapeutics.

​

Treatment Modalities in the Current Market

The PTSD treatment market encompasses several distinct categories of intervention. Psychotherapy, including cognitive behavioral therapy, prolonged exposure therapy, and eye movement desensitization and reprocessing, represents a major segment. Medication, including antidepressants, anti-anxiety medications, and sleep aids, represents another substantial segment. Self-help strategies, including exercise, relaxation techniques, and mindfulness meditation, constitute a growing segment driven by consumer demand for non-pharmacological options. Support groups and group therapy offer community and understanding for people with PTSD, creating a safe and supportive space for sharing stories and learning coping skills.

​

SAMANSIC's Addressable Opportunity

Within this $16.8 to $27.37 billion market, SAMANSIC's addressable opportunity lies in the nutritional supplement segment for mental health, which is a substantial but less precisely quantified adjacent market. The differentiation of SAMANSIC's approach comes from its mechanism-driven strategy targeting SUMOylation and peptide-mediated neuroprotection, as opposed to generic supplements lacking specific mechanistic claims. Target populations include PTSD patients with treatment resistance, those with comorbid neurodegenerative risk, and individuals who desire non-pharmacological or adjunctive options to complement standard care.

​

VII. Strategic Integration of the KAN V1.0 Artificial Intelligence Architecture

​

Overview of the KAN V1.0 Platform

The Kinematic Acceleration Nullifier, designated KAN V1.0, is an artificial intelligence-driven multi-omic integration engine that serves as the core personalization technology for the SAMANSIC platform. The system is designed to analyze individual genomic, microbiomic, lifestyle, and clinical data streams and to generate phenotype-specific nutritional formulations based on this integrated analysis. This approach moves beyond population-level guidance to enable preemptive, individualized metabolic health optimization.

​

Application to PTSD and Neuroprotection

In the context of PTSD and neuroprotection, the KAN V1.0 platform can be applied to identify individual variations in SUMOylation capacity, stress hormone regulation pathways, and mitochondrial efficiency. Based on this molecular profiling, the system can tailor DK-NEURO R150 peptide blends and adjust the ratios of the Four Pillars components to each patient's unique biochemical phenotype. Furthermore, the platform can monitor treatment response over time using digital biomarkers derived from wearable devices, self-reported symptom assessments, and cognitive testing, enabling real-time adaptation of the nutritional intervention.

​

Clinical Validation Imperative

Despite the scientific plausibility of this approach, rigorous clinical validation is required before the KAN V1.0 platform can be considered evidence-based. Randomized controlled trials are necessary to demonstrate the superiority of KAN V1.0-guided nutrition over fixed-formula comparators or placebo. Endpoints for such trials should include validated measures of PTSD symptom severity, such as the Clinician-Administered PTSD Scale for DSM-5, biomarkers of SUMOylation measured in peripheral blood mononuclear cells, and functional measures of mitochondrial capacity such as the lactate to pyruvate ratio or ATP production rates.

​

VIII. Regulatory and Clinical Validation Roadmap

​

Current Regulatory Status

As of the date of this report, DK-NEURO R150 is positioned as a nutritional supplement and has not received approval from the United States Food and Drug Administration or any comparable regulatory agency as a drug for the treatment of PTSD or any other medical condition. The SUMOylation-targeting Four Pillars protocol is proposed for FDA Medical Food designation for sarcopenia, which is considered a more feasible regulatory pathway than for PTSD, and as a dietary supplement for PTSD and neuroprotection.

​

Critical Regulatory Risks

Several significant regulatory risks must be acknowledged. The FDA may classify PTSD-related claims as drug claims rather than supplement or medical food claims, which would require the submission of a full New Drug Application and the completion of Phase 1, Phase 2, and Phase 3 clinical trials before any marketing could occur. There is currently no published human evidence demonstrating that oral intake of the Four Pillars components increases SUMOylation activity in any tissue, let alone in the central nervous system. Peptide-based supplements, including DK-NEURO R150, face substantial challenges related to oral bioavailability, gastrointestinal degradation, and stability during manufacturing and storage.

​

Recommended Validation Pathway

• The following validation pathway is recommended to establish the scientific and regulatory credibility of the SAMANSIC platform. During the preclinical phase, which is described as already completed, in vitro and animal studies of SUMOylation modulation would have been conducted at an estimated cost of approximately $2 million.

• Phase zero, targeted for 2026, would consist of a human pharmacokinetic and pharmacodynamic study with biomarker endpoints to determine whether oral administration of the Four Pillars protocol produces measurable changes in SUMOylation-related biomarkers in peripheral blood. This phase is estimated to cost $1.5 million.

• Phase one, targeted for 2027, would be a safety and tolerability study in healthy volunteers to establish the safety profile of the combined intervention at proposed therapeutic doses. This phase is estimated to cost $2 million.

• Phase two A, targeted for 2028 to 2029, would be a proof-of-concept study in PTSD patients with approximately 100 to 150 participants, designed to detect preliminary signals of efficacy on biomarker and clinical endpoints. This phase is estimated to cost $5 million.

• Phase two B and Phase three, targeted for 2030 to 2033, would consist of a large randomized controlled trial comparing the SAMANSIC intervention plus standard care to placebo plus standard care, with PTSD symptom severity as the primary endpoint. This phase is estimated to cost $15 to $25 million.

​

IX. Discussion and Scientific Limitations

​

Strengths of the SAMANSIC Approach

The SAMANSIC approach has several notable strengths from a scientific perspective. First, it is mechanistically grounded in peer-reviewed SUMOylation biology that has been validated in multiple preclinical models across different laboratories. Second, the dual-use narrative, which positions space-derived countermeasures as applicable to terrestrial aging and stress-related disorders, provides a unique marketing differentiation that is scientifically plausible even if not yet proven. Third, the AI-driven personalization offered by KAN V1.0 addresses the well-recognized heterogeneity of PTSD and the aging process, potentially improving upon one-size-fits-all approaches that have shown limited efficacy in subsets of patients.

​

Critical Limitations and Unanswered Questions

Several critical limitations must be acknowledged transparently. There are no published human data linking DK-NEURO R150 or the Four Pillars protocol to increased SUMOylation activity or to clinically meaningful reductions in PTSD symptoms. The regulatory pathway for PTSD-related nutritional claims remains highly uncertain, and the FDA may require full drug approval rather than allowing medical food or supplement designations. The market projections, while derived from reputable sources for the overall PTSD treatment market, may overestimate the potential adoption of a nutritional intervention given the current lack of insurance reimbursement for such products and the dominance of established psychotherapies and pharmacotherapies.

​

Furthermore, the relationship between peripheral biomarkers of SUMOylation and central nervous system SUMOylation activity is not well established, meaning that even if the Four Pillars protocol increases SUMOylation in blood cells, this may not reflect meaningful changes in the brain. The oral bioavailability of the peptides in DK-NEURO R150 has not been demonstrated, and it is possible that these peptides are degraded in the gastrointestinal tract before reaching systemic circulation or crossing the blood-brain barrier.

​

Recommended Next Steps

Based on this analysis, the following next steps are recommended for the SAMANSIC Coalition. First, publish a peer-reviewed mechanistic review article linking SUMOylation to PTSD pathophysiology to establish the scientific rationale in the formal literature. Second, conduct an open-label pilot study of DK-NEURO R150 in 30 PTSD patients to generate preliminary safety and tolerability data and to refine outcome measures for larger trials. Third, file a pre-submission meeting request with the FDA to obtain formal guidance on the regulatory pathway for the proposed indications, which will clarify whether medical food, dietary supplement, or drug classification is required. Fourth, develop a partnership with an academic medical center that has expertise in PTSD clinical trials and biomarker validation to ensure rigorous execution of the validation pathway.

​

X. Conclusion

• The SAMANSIC Coalition has assembled a scientifically coherent and commercially ambitious platform targeting PTSD, neurodegeneration, and stress-related disorders through peptide-based nutrition and SUMOylation pathway support. The mechanistic rationale draws on legitimate preclinical literature demonstrating that SUMOylation plays a protective role in neuronal health, that bioactive peptides can exert neurotrophic and anti-inflammatory effects, and that chronic stress hormone exposure damages neural networks through excitotoxic and ischemic mechanisms.

• The global PTSD treatment market, valued at $16.8 billion in 2023 and projected to reach $27.37 billion by 2033, offers substantial commercial opportunity for a differentiated, mechanism-driven intervention. However, the transition from preclinical plausibility to human clinical validation remains the critical path that will determine the scientific and commercial viability of the SAMANSIC platform.

• Success will require rigorous clinical trials demonstrating that the Four Pillars protocol increases SUMOylation activity in humans, that DK-NEURO R150 achieves meaningful bioavailability and target engagement in the nervous system, and that the combined intervention produces clinically significant reductions in PTSD symptoms beyond those achieved by standard care alone. A clear regulatory strategy must be established in consultation with the FDA, and realistic positioning as an adjunctive rather than replacement therapy for established psychotherapies and pharmacotherapies is essential.

• The SAMANSIC Coalition is therefore advised to prioritize the publication of foundational mechanistic data, the completion of early-phase human studies with biomarker endpoints, and the establishment of academic partnerships for rigorous clinical trial execution before proceeding with large-scale commercial deployment. The scientific foundation is plausible, but the evidentiary gap between preclinical promise and clinical proof remains substantial and must be systematically addressed.

​

XI. References

• Mayo Clinic. Post-traumatic stress disorder, diagnosis and treatment. Retrieved from mayoclinic.org.

• American Psychological Association. Clinical practice guideline for the treatment of post-traumatic stress disorder. 2019.

• National Health Service United Kingdom. Post-traumatic stress disorder treatment. Retrieved from nhs.uk.

• Future Market Insights. Post-traumatic stress disorder treatment market outlook 2023 to 2033.

• Global Peptide Therapeutics Market Report. 2023.

• Peer-reviewed SUMOylation literature 2023 to 2025 as cited in SAMANSIC internal documents.

• Journal of Cachexia, Sarcopenia and Muscle. SUMOylation as a regulator of muscle growth, repair, and aging. 2023.

• High-impact Parkinson's disease studies. SUMO-2/3 conjugation and mitochondrial protection. 2024.

• Cell biology studies of SUMOylation and lifespan extension in Caenorhabditis elegans.

• Cardiovascular research studies on SUMO2 modification of p66Shc and endothelial dysfunction. 2024 to 2025.

​

XII. Appendices

• Appendix A provides detailed technical architecture of the KAN V1.0 artificial intelligence platform, including data integration protocols and algorithmic weighting methods.

• Appendix B summarizes preclinical SUMOylation data from in vitro and animal model studies cited in SAMANSIC internal documents.

• Appendix C presents DK-NEURO R150 formulation specifications, including peptide sources, concentrations, and manufacturing quality controls.

• Appendix D contains draft regulatory correspondence for FDA pre-submission meeting requests and medical food designation filings.

• Appendix E presents the investor financial model for the 2026 to 2036 period, including capital allocation, revenue projections, and return on investment calculations.

​

End of Scientific Report

​